Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2.

Publication Type:

Journal Article

Source:

Vaccine, Volume 29, Issue 40, p.7058-66 (2011)

Keywords:

2011, Adult, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Center-Authored Paper, Enzyme-Linked Immunospot Assay, Epitopes, T-Lymphocyte, Female, Herpes Simplex Virus Vaccines, Herpesvirus 1, Human, Herpesvirus 2, Human, Humans, Immediate-Early Proteins, interferon-gamma, Male, Middle Aged, Peptides, PHENOTYPE, September 2011, Vaccine and Infectious Disease Division

Abstract:

The need for an HSV-2 vaccine is great considering the increasing prevalence of HSV-2 despite the widespread use of antiviral drugs. Human clinical trials of HSV-2 vaccines that elicit neutralizing antibodies have proven to be only partially effective suggesting that induction of effective T cell responses to HSV-2 is also a critical component to an efficacious vaccine. A sensitive and specific assay to measure HSV-specific T cell responses is a necessary part of vaccine development and thus we undertook the development of an interferon-γ (IFN-γ) ELISPOT assay to measure T cell responses to HSV-2.